サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1523035

カルシウム拮抗剤市場レポート：2030年までの動向、予測、競合分析

Calcium Channel Blockers Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日
発行
Lucintel
ページ情報
英文 150 Pages
納期
3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

カルシウム拮抗剤市場レポート：2030年までの動向、予測、競合分析
出版日: 2024年07月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

カルシウム拮抗剤の動向と予測

世界のカルシウム拮抗剤市場は、2024年から2030年にかけてCAGR 5.4％で成長すると予測されます。この市場の主な促進要因は、高齢者人口の大幅な増加、複合的な治療アプローチへのアクセスの増加、心血管疾患の有病率の増加です。カルシウム拮抗剤の世界市場の将来は、高血圧、狭心症、不整脈、肥大型心筋症市場に機会があり、有望視されています。

セグメント別カルシウム拮抗剤

薬剤クラス別、投与経路別、流通チャネル別、用途別、地域別のカルシウム拮抗剤の世界市場予測を掲載しています。

カルシウム拮抗剤市場の洞察

Lucintel社の予測では、ジヒドロピリジンは高血圧治療への採用が増加しているため、予測期間中も最大セグメントであり続けます。

この市場において、高血圧は引き続き最大のセグメントです。

北米は心血管疾患の有病率が高く、高齢化も進んでいるため、予測期間中も最大セグメントであり続けるでしょう。

よくある質問

Q1.市場の成長予測は：

A1.世界のカルシウム拮抗剤市場は、2024年から2030年にかけてCAGR 5.4％で成長すると予想されています。

Q2.市場の成長に影響を与える主な促進要因は：

A2.この市場の主な促進要因は、高齢者人口の大幅な増加、複合的な治療アプローチへのアクセスの増加、心血管疾患の有病率の増加です。

Q3.市場の主要セグメントは：

A3.カルシウム拮抗剤市場の将来は、高血圧、狭心症、不整脈、肥大型心筋症市場に機会があり、有望です。

Q4.市場の主要企業は：

A4.カルシウム拮抗剤の主要企業は以下の通りです：

  • Pfizer
  • Teva Pharmaceutical Industries
  • Bausch Health Company
  • Novartis
  • AstraZeneca
  • Merck
  • GSK
  • Bayer
  • Sun Pharmaceutical Industries
  • Daiichi Sankyo

Q5.今後、最大となる市場セグメントは：

A5.Lucintelは、ジヒドロピリジンは高血圧治療への採用が増加しているため、予測期間中も最大セグメントであり続けると予測しています。

Q6.市場において、今後5年間に最大になると予想される地域は：

A6.北米は心血管疾患の有病率が高く、高齢化も進んでいるため、予測期間中も最大セグメントであり続けます。

Q7.レポートのカスタマイズは可能か：

A7.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界のカルシウム拮抗剤市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界のカルシウム拮抗剤市場の動向（2018-2023年）と予測（2024-2030年）
  • 世界のカルシウム拮抗剤市場：薬剤クラス別
    • フェニルアルキルアミン
    • ベンゾチゼピン
    • ジヒドロピリジン
  • 世界のカルシウム拮抗剤市場：投与経路別
    • 経口
    • 非経口
  • 世界のカルシウム拮抗剤市場：流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 世界のカルシウム拮抗剤市場：用途別
    • 高血圧
    • 狭心症
    • 不整脈
    • 肥大型心筋症
    • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

  • 地域別カルシウム拮抗剤の世界市場
  • 北米のカルシウム拮抗剤市場
  • 欧州のカルシウム拮抗剤市場
  • アジア太平洋地域のカルシウム拮抗剤市場
  • その他地域カルシウム拮抗剤市場

第5章 競合分析

  • 製品ポートフォリオ分析
  • 運用統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
    • 薬剤クラス別の世界のカルシウム拮抗剤市場の成長機会
    • 投与経路別の世界のカルシウム拮抗剤市場の成長機会
    • 流通チャネル別世界のカルシウム拮抗剤市場の成長機会
    • 用途別カルシウム拮抗剤の世界市場の成長機会
    • 地域別の世界のカルシウム拮抗剤市場の成長機会
  • 世界のカルシウム拮抗剤市場の新たな動向
  • 戦略分析
    • 新製品の開発
    • 世界のカルシウム拮抗剤市場の生産能力拡大
    • 世界のカルシウム拮抗剤市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 主要企業の企業プロファイル

  • Pfizer
  • Teva Pharmaceutical Industries
  • Bausch Health Company
  • Novartis
  • AstraZeneca
  • Merck
  • GSK
  • Bayer
  • Sun Pharmaceutical Industries
  • Daiichi Sankyo
目次

Calcium Channel Blockers Trends and Forecast

The future of the global calcium channel blockers market looks promising with opportunities in the hypertension, angina, arrhythmia, and hypertrophic cardiomyopathy markets. The global calcium channel blockers market is expected to grow with a CAGR of 5.4% from 2024 to 2030. The major drivers for this market are significant surge in the elderly demographic, increasing accessibility of combined therapeutic approaches, and growing prevalence rate of cardiovascular diseases.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Calcium Channel Blockers by Segment

The study includes a forecast for the global calcium channel blockers by drug class, route of administration, distribution channel, application, and region.

Calcium Channel Blockers Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Phenylalkylamine
  • Benzothizepine
  • Dihydropyridine

Calcium Channel Blockers Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Parenteral

Calcium Channel Blockers Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Calcium Channel Blockers Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hypertension
  • Angina
  • Arrhythmia
  • Hypertrophic Cardiomyopathy
  • Others

Calcium Channel Blockers Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Calcium Channel Blockers Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies calcium channel blockers companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the calcium channel blockers companies profiled in this report include-

  • Pfizer
  • Teva Pharmaceutical Industries
  • Bausch Health Company
  • Novartis
  • AstraZeneca
  • Merck
  • GSK
  • Bayer
  • Sun Pharmaceutical Industries
  • Daiichi Sankyo

Calcium Channel Blockers Market Insights

Lucintel forecasts that dihydropyridine will remain the largest segment over the forecast period due to its increasing adoption for treating hypertension.

Within this market, hypertension will remain the largest segment.

North America will remain the largest segment over the forecast period due to high prevalence of cardiovascular diseases and rising aging population in the region.

Features of the Global Calcium Channel Blockers Market

Market Size Estimates: Calcium channel blockers market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Calcium channel blockers market size by various segments, such as by drug class, route of administration, distribution channel, application, and region in terms of value ($B).

Regional Analysis: Calcium channel blockers market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, route of administration, distribution channels, application, and regions for the calcium channel blockers market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the calcium channel blockers market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for calcium channel blockers market?

Answer: The global calcium channel blockers market is expected to grow with a CAGR of 5.4% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the calcium channel blockers market?

Answer: The major drivers for this market are significant surge in the elderly demographic, increasing accessibility of combined therapeutic approaches and growing prevalence rate of cardiovascular diseases.

Q3. What are the major segments for calcium channel blockers market?

Answer: The future of the calcium channel blockers market looks promising with opportunities in the hypertension, angina, arrhythmia, and hypertrophic cardiomyopathy markets.

Q4. Who are the key calcium channel blockers market companies?

Answer: Some of the key calcium channel blockers companies are as follows:

  • Pfizer
  • Teva Pharmaceutical Industries
  • Bausch Health Company
  • Novartis
  • AstraZeneca
  • Merck
  • GSK
  • Bayer
  • Sun Pharmaceutical Industries
  • Daiichi Sankyo

Q5. Which calcium channel blockers market segment will be the largest in future?

Answer: Lucintel forecasts that dihydropyridine will remain the largest segment over the forecast period due to its increasing adoption for treating hypertension.

Q6. In calcium channel blockers market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to high prevalence of cardiovascular diseases and rising aging population in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the calcium channel blockers market by drug class (phenylalkylamine, benzothizepine, and dihydropyridine), route of administration (oral and parenteral), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), application (hypertension, angina, arrhythmia, hypertrophic cardiomyopathy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Calcium Channel Blockers Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Calcium Channel Blockers Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Calcium Channel Blockers Market by Drug Class
    • 3.3.1: Phenylalkylamine
    • 3.3.2: Benzothizepine
    • 3.3.3: Dihydropyridine
  • 3.4: Global Calcium Channel Blockers Market by Route of Administration
    • 3.4.1: Oral
    • 3.4.2: Parenteral
  • 3.5: Global Calcium Channel Blockers Market by Distribution Channel
    • 3.5.1: Hospital Pharmacies
    • 3.5.2: Retail Pharmacies
    • 3.5.3: Online Pharmacies
  • 3.6: Global Calcium Channel Blockers Market by Application
    • 3.6.1: Hypertension
    • 3.6.2: Angina
    • 3.6.3: Arrhythmia
    • 3.6.4: Hypertrophic Cardiomyopathy
    • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Calcium Channel Blockers Market by Region
  • 4.2: North American Calcium Channel Blockers Market
    • 4.2.1: North American Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
    • 4.2.2: North American Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others
  • 4.3: European Calcium Channel Blockers Market
    • 4.3.1: European Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
    • 4.3.2: European Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others
  • 4.4: APAC Calcium Channel Blockers Market
    • 4.4.1: APAC Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
    • 4.4.2: APAC Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others
  • 4.5: ROW Calcium Channel Blockers Market
    • 4.5.1: ROW Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
    • 4.5.2: ROW Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Calcium Channel Blockers Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Calcium Channel Blockers Market by Route of Administration
    • 6.1.3: Growth Opportunities for the Global Calcium Channel Blockers Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global Calcium Channel Blockers Market by Application
    • 6.1.5: Growth Opportunities for the Global Calcium Channel Blockers Market by Region
  • 6.2: Emerging Trends in the Global Calcium Channel Blockers Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Calcium Channel Blockers Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Calcium Channel Blockers Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Pfizer
  • 7.2: Teva Pharmaceutical Industries
  • 7.3: Bausch Health Company
  • 7.4: Novartis
  • 7.5: AstraZeneca
  • 7.6: Merck
  • 7.7: GSK
  • 7.8: Bayer
  • 7.9: Sun Pharmaceutical Industries
  • 7.10: Daiichi Sankyo